Loading…
Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.
Institutional pharmacy operator dispensing medications to residents of senior living and long-term care facilities.
Dispenses medications resident by resident and is paid per prescription, mainly by Medicare Part D drug plans, Medicaid and private payers rather than the facility itself. It operates through a set of local pharmacies, each close to the facilities it serves, and has grown by buying small institutional pharmacies.
Moat: narrow (switching costs, scale, regulatory licence). Facility contracts and integrated dispensing systems are disruptive and costly for operators to switch.
Headquarters: Atlanta, Georgia, US · Employees: 3,600
Size Guardian Pharmacy Services (GRDN) is a United States Consumer Staples company (Drugstore Chains) with a market value of $2.68B, the 1606th largest of 3,117 United States companies the cockpit tracks. Shares closed at $42.39 on 6 Nov 2026.
Performance Over six months the shares gained 17.5%, against +4.6% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 15 in its peer set.
Growth Revenue grew 10.3% over the last twelve months (peer median +8.5%); the operating margin is 5.7% (peer median 4.8%).
Valuation It trades at 30.6× forward earnings against a peer median of 16.8× (2nd most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 24.4 points above its cost of capital (6.3% WACC).
Short interest Short interest is 4.8% of the free float (15 Oct 2026).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.46B | $1.45B | $1.23B | $1.05B | $909M |
| Revenue growth | — | +18% | +17% | +15% | — |
| Gross profit | $317M | $282M | $235M | $200M | $178M |
| EBITDA | $107M | $111M | -$43.1M | $59.2M | $68.6M |
| Net income | $65.9M | $49.2M | -$110M | $23.9M | $35.4M |
| Free cash flow | $79.8M | $80.7M | $41.6M | $56.3M | $31.8M |
| Capital expenditure | $19.1M | $19.5M | $16.4M | $14.6M | $16.8M |
| Total debt | $35.2M | $44.7M | $37.3M | $68.2M | $63.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services GRDN | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% |
| CVS Health CVS | $107B | -7% | +7% | 4% | 9.9× | -3.9% |
| BrightSpring Health Services BTSG | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GRDN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | +6.7% | 5th lowest of 15 |
| 6-month return | +17.5% | +4.6% | highest of 15 |
| Distance from 52-week high | -12.3% | -18.9% | 6th highest of 15 |
| Revenue growth (TTM) | +10.3% | +8.5% | 5th highest of 15 |
| Operating margin | 5.7% | 4.8% | 5th highest of 15 |
| Forward P/E | 30.6× | 16.8× | 2nd most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 4.1% | -8.0% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +16.8% | +13.2% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -12.7 pp | -20.6 pp | 3rd most demanding of 14 |
| ROIC minus cost of capital | +24.4 pp | +6.9 pp | highest of 15 |
| EV / EBITDA | 24.7× | 7.3× | most expensive of 9 |
| Net debt / EBITDA | -0.5× | 0.1× | 3rd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |
| Sugi 7649.T | Japan | $3.27B | -23% | +9% | 5% | 16.8× | -9.7% | +10.9% |
| DaShenLin Pharmaceutical 603233.SS | China | $3.80B | +15% | +7% | 8% | 16.6× | -9.0% | +13.6% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| Yifeng Pharmacy Chain 603939.SS | China | $4.91B | +17% | +5% | 10% | 17.2× | -9.2% | +13.2% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| TSURUHA 3391.T | Japan | $6.74B | +15% | +114% | 4% | 22.2× | -2.3% | +9.6% |
| MatsukiyoCocokara & 3088.T | Japan | $6.78B | +17% | +5% | 8% | 17.5× | -6.2% | +15.5% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |